temozolomide has been researched along with Dermatitis Medicamentosa in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers." | 7.76 | Urticarial hypersensitivity reaction caused by temozolomide. ( Hsu, MY; Ibrahimi, OA; Kesari, S; Pothiawala, S; Yang, C, 2010) |
| "Temozolomide is an oral alkylating agent used in the treatment of metastatic melanoma." | 7.74 | Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma. ( Neff, WJ; Nystrom, KK; Pick, AM, 2008) |
| "Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers." | 3.76 | Urticarial hypersensitivity reaction caused by temozolomide. ( Hsu, MY; Ibrahimi, OA; Kesari, S; Pothiawala, S; Yang, C, 2010) |
| "Temozolomide is an oral alkylating agent used in the treatment of metastatic melanoma." | 3.74 | Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma. ( Neff, WJ; Nystrom, KK; Pick, AM, 2008) |
| "We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors." | 2.73 | Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. ( Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD, 2008) |
| "Necrolytic migratory erythema is an obligatory paraneoplastic syndrome." | 1.39 | Necrolytic migratory erythema in a patient with neuroendocrine carcinoma. ( Enk, AH; Gronau, M; Hassel, JC; Jäger, D, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jakacki, RI | 1 |
| Hamilton, M | 1 |
| Gilbertson, RJ | 1 |
| Blaney, SM | 1 |
| Tersak, J | 1 |
| Krailo, MD | 1 |
| Ingle, AM | 1 |
| Voss, SD | 1 |
| Dancey, JE | 1 |
| Adamson, PC | 1 |
| Pothiawala, S | 1 |
| Hsu, MY | 1 |
| Yang, C | 1 |
| Kesari, S | 1 |
| Ibrahimi, OA | 1 |
| Gronau, M | 1 |
| Jäger, D | 1 |
| Enk, AH | 1 |
| Hassel, JC | 1 |
| Pick, AM | 1 |
| Neff, WJ | 1 |
| Nystrom, KK | 1 |
1 trial available for temozolomide and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; | 2008 |
3 other studies available for temozolomide and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Urticarial hypersensitivity reaction caused by temozolomide.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Da | 2010 |
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neur | 2013 |
Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Ski | 2008 |